Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatectomy plus postoperative FOLFOX4 vs hepatectomy alone for hepatocellular carcinoma with microvascular invasion
ChiCTR2000035478Phase 3Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Aug 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin + fluorouracil + leucovorin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Disease-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
oxaliplatin + fluorouracil + leucovorin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000035478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035478.